Literature DB >> 28471656

4-Anilino-2-pyridylquinazolines and -pyrimidines as Highly Potent and Nontoxic Inhibitors of Breast Cancer Resistance Protein (ABCG2).

Michael K Krapf1, Jennifer Gallus1, Michael Wiese1.   

Abstract

Multidrug resistance (MDR) mediated by ATP-binding cassette (ABC) transport proteins remains a major problem in the chemotherapeutic treatment of cancer and might be overcome by inhibition of the transporter. Because of the lack of understanding, the complex mechanisms involved in the transport process, in particular for breast cancer resistance protein (BCRP/ABCG2), there is a persistent need for studies of inhibitors of ABCG2. In this study, we investigated a systematic series of 4-substituted-2-pyridylquinazolines in terms of their inhibitory potency as well as selectivity toward ABCG2. For comparison, the quinazoline scaffold was reduced to the significantly smaller 4-methylpyrimidine basic structure. Furthermore, the cytotoxicity and the ability to reverse MDR was tested with the chemotherapeutic agents SN-38 and mitoxantrone (MX). Interaction of the compounds with ABCG2 was investigated by a colorimetric ATPase assay. Enzyme kinetic studies were carried out with Hoechst 33342 as fluorescent dye and substrate of ABCG2 to elucidate the compounds binding modes.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28471656     DOI: 10.1021/acs.jmedchem.7b00441

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

1.  Design and evaluation of pyrimidine derivatives as potent inhibitors of ABCG2, a breast cancer resistance protein.

Authors:  Shahnawaz Ahmad; Md Imtaiyaz Hassan; Dinesh Gupta; Neeraj Dwivedi; Asimul Islam
Journal:  3 Biotech       Date:  2022-07-19       Impact factor: 2.893

2.  Development of Simple and Accurate in Silico Ligand-Based Models for Predicting ABCG2 Inhibition.

Authors:  Shuheng Huang; Yingjie Gao; Xuelian Zhang; Ji Lu; Jun Wei; Hu Mei; Juan Xing; Xianchao Pan
Journal:  Front Chem       Date:  2022-05-18       Impact factor: 5.545

3.  ADMET evaluation in drug discovery. 20. Prediction of breast cancer resistance protein inhibition through machine learning.

Authors:  Dejun Jiang; Tailong Lei; Zhe Wang; Chao Shen; Dongsheng Cao; Tingjun Hou
Journal:  J Cheminform       Date:  2020-03-05       Impact factor: 5.514

Review 4.  Recent advances in the search of BCRP- and dual P-gp/BCRP-based multidrug resistance modulators.

Authors:  Silvia Dei; Laura Braconi; Maria Novella Romanelli; Elisabetta Teodori
Journal:  Cancer Drug Resist       Date:  2019-09-19

5.  Copper mediated one-pot synthesis of quinazolinones and exploration of piperazine linked quinazoline derivatives as anti-mycobacterial agents.

Authors:  Satyaveni Malasala; Jitendra Gour; Md Naiyaz Ahmad; Srikanth Gatadi; Manjulika Shukla; Grace Kaul; Arunava Dasgupta; Y V Madhavi; Sidharth Chopra; Srinivas Nanduri
Journal:  RSC Adv       Date:  2020-12-08       Impact factor: 4.036

6.  Overcoming Multidrug Resistance (MDR): Design, Biological Evaluation and Molecular Modelling Studies of 2,4-Substituted Quinazoline Derivatives.

Authors:  Laura Braconi; Elisabetta Teodori; Marialessandra Contino; Chiara Riganti; Gianluca Bartolucci; Dina Manetti; Maria Novella Romanelli; Maria Grazia Perrone; Nicola Antonio Colabufo; Stefano Guglielmo; Silvia Dei
Journal:  ChemMedChem       Date:  2022-05-12       Impact factor: 3.540

7.  Structure-Based Discovery of ABCG2 Inhibitors: A Homology Protein-Based Pharmacophore Modeling and Molecular Docking Approach.

Authors:  Minh-Tri Le; Viet-Nham Hoang; Dac-Nhan Nguyen; Thi-Hoang-Linh Bui; Thien-Vy Phan; Phuong Nguyen-Hoai Huynh; Thanh-Dao Tran; Khac-Minh Thai
Journal:  Molecules       Date:  2021-05-23       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.